naltrexone has been researched along with nystatin a1 in 5 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (60.00) | 29.6817 |
2010's | 2 (40.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Chang, HK; Han, SM; Jang, MH; Kim, CJ; Kim, KA; Lee, JS; Lim, S; Park, HJ; Shim, I; Shin, MC | 1 |
Abe, K; Shirasaki, T; Soeda, F; Takahama, K | 1 |
1 review(s) available for naltrexone and nystatin a1
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
4 other study(ies) available for naltrexone and nystatin a1
Article | Year |
---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Modulation of Chelidonii herba on glycine-activated and glutamate-activated ion currents in rat periaqueductal gray neurons.
Topics: Animals; Chelidonium; Dose-Response Relationship, Drug; Ethylmaleimide; Female; Glutamic Acid; Glycine; Ion Channel Gating; Male; Membrane Potentials; Naltrexone; Neurons; Nystatin; Patch-Clamp Techniques; Periaqueductal Gray; Plant Extracts; Rats; Rats, Sprague-Dawley | 2003 |
delta-Opioid receptor antagonists inhibit GIRK channel currents in acutely dissociated brainstem neurons of rat.
Topics: Analgesics, Opioid; Animals; Animals, Newborn; Cells, Cultured; Dose-Response Relationship, Drug; Drug Interactions; Enkephalin, D-Penicillamine (2,5)-; G Protein-Coupled Inwardly-Rectifying Potassium Channels; Guanosine 5'-O-(3-Thiotriphosphate); Ionophores; Locus Coeruleus; Naltrexone; Narcotic Antagonists; Neurons; Norepinephrine; Nystatin; Patch-Clamp Techniques; Potassium Channels; Potassium Channels, Inwardly Rectifying; Raphe Nuclei; Rats; Serotonin; Thermolysin | 2004 |